Gen Hirano

674 total citations
22 papers, 549 citations indexed

About

Gen Hirano is a scholar working on Oncology, Molecular Biology and Surgery. According to data from OpenAlex, Gen Hirano has authored 22 papers receiving a total of 549 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Molecular Biology and 7 papers in Surgery. Recurrent topics in Gen Hirano's work include Gastric Cancer Management and Outcomes (6 papers), Colorectal Cancer Treatments and Studies (4 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (4 papers). Gen Hirano is often cited by papers focused on Gastric Cancer Management and Outcomes (6 papers), Colorectal Cancer Treatments and Studies (4 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (4 papers). Gen Hirano collaborates with scholars based in Japan, China and Canada. Gen Hirano's co-authors include Hiroto Izumi, Kimitoshi Kohno, Akihiko Kidani, Eiji Kashiwagi, Naoya Miyamoto, Masaki Shiota, Yoshihiro Yasuniwa, Hitoshi Kusaba, Yasuyuki Sasaguri and Koichi Akashi and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Gen Hirano

21 papers receiving 541 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gen Hirano Japan 13 314 214 96 95 72 22 549
Islay Steele United Kingdom 15 291 0.9× 203 0.9× 61 0.6× 116 1.2× 211 2.9× 20 655
Feridoon Najmabadi United States 11 634 2.0× 254 1.2× 55 0.6× 84 0.9× 43 0.6× 14 827
Αναστασία Κοττόρου Greece 15 245 0.8× 172 0.8× 71 0.7× 175 1.8× 27 0.4× 37 510
G Ballabio Italy 3 380 1.2× 312 1.5× 87 0.9× 161 1.7× 56 0.8× 6 688
Huan-Xin Lin China 12 248 0.8× 136 0.6× 74 0.8× 110 1.2× 58 0.8× 15 477
Stefan Amatschek Austria 9 297 0.9× 185 0.9× 60 0.6× 93 1.0× 64 0.9× 9 567
Chiyuki Furukawa Japan 5 269 0.9× 126 0.6× 97 1.0× 69 0.7× 17 0.2× 6 434
D Chatterjee United States 9 365 1.2× 126 0.6× 38 0.4× 109 1.1× 31 0.4× 17 497
Jae Hwi Song South Korea 16 388 1.2× 131 0.6× 56 0.6× 89 0.9× 85 1.2× 27 568
Eveline Barbieri United States 14 435 1.4× 250 1.2× 52 0.5× 246 2.6× 22 0.3× 23 727

Countries citing papers authored by Gen Hirano

Since Specialization
Citations

This map shows the geographic impact of Gen Hirano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gen Hirano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gen Hirano more than expected).

Fields of papers citing papers by Gen Hirano

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gen Hirano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gen Hirano. The network helps show where Gen Hirano may publish in the future.

Co-authorship network of co-authors of Gen Hirano

This figure shows the co-authorship network connecting the top 25 collaborators of Gen Hirano. A scholar is included among the top collaborators of Gen Hirano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gen Hirano. Gen Hirano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Kusaba, Hitoshi, Takeharu Yamanaka, Kenta Nio, et al.. (2018). A phase 2 study of fosaprepitant combined with high-dose dexamethasone for Japanese cancer patients receiving highly emetogenic chemotherapy. Medicine. 97(25). e11042–e11042. 2 indexed citations
4.
Makiyama, Akitaka, et al.. (2018). A retrospective study to compare TAS-102 with TAS-102+BV in advanced colorectal cancer refractory to standard therapy. Annals of Oncology. 29. vii75–vii75. 2 indexed citations
5.
6.
Makiyama, Akitaka, Gen Hirano, Tsuyoshi Shirakawa, et al.. (2017). Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer. Gastric Cancer. 21(3). 464–472. 38 indexed citations
7.
Ito, Mamoru, Hitoshi Kusaba, Junji Kishimoto, et al.. (2017). Early tumor shrinkage indicates a favorable response to bevacizumab-based first-line chemotherapy for metastatic colorectal cancer. Anti-Cancer Drugs. 28(10). 1166–1173. 3 indexed citations
8.
Kusaba, Hitoshi, Risa Tanaka, Kenji Mitsugi, et al.. (2017). Efficacy and Safety Analysis of Oxaliplatin-based Chemotherapy for Advanced Gastric Cancer. Anticancer Research. 37(5). 2663–2671. 16 indexed citations
9.
Arita, Shuji, Tsuyoshi Shirakawa, Gen Hirano, et al.. (2016). Efficacy and Safety of TAS-102 in Clinical Practice of Salvage Chemotherapy for Metastatic Colorectal Cancer.. PubMed. 36(4). 1959–66. 16 indexed citations
10.
Hirano, Gen, et al.. (2015). Salvage line CPT-11 after failure of fluoropyrimidine and paclitaxel-based chemotherapy in advanced gastric cancer. Annals of Oncology. 26. vii133–vii133. 1 indexed citations
11.
Nio, Kenta, Shuji Arita, Taichi Isobe, et al.. (2015). Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy. Cancer Chemotherapy and Pharmacology. 75(4). 829–835. 14 indexed citations
12.
Hirano, Gen, Akitaka Makiyama, Taito Esaki, et al.. (2015). Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan.. PubMed. 35(1). 371–7. 12 indexed citations
13.
Uchino, Keita, Gen Hirano, Minako Hirahashi, et al.. (2012). Human Nanog pseudogene8 promotes the proliferation of gastrointestinal cancer cells. Experimental Cell Research. 318(15). 1799–1807. 26 indexed citations
14.
Takahashi, Mayu, Shohei Shimajiri, Hiroto Izumi, et al.. (2010). Y‐box binding protein‐1 is a novel molecular target for tumor vessels. Cancer Science. 101(6). 1367–1373. 41 indexed citations
15.
Yasuniwa, Yoshihiro, Hiroto Izumi, Ke‐Yong Wang, et al.. (2010). Circadian Disruption Accelerates Tumor Growth and Angio/Stromagenesis through a Wnt Signaling Pathway. PLoS ONE. 5(12). e15330–e15330. 54 indexed citations
16.
Makiyama, Akitaka, Keita Uchino, Yoshihiro Shibata, et al.. (2009). Schedule-dependent synergistic interaction between gemcitabine and oxaliplatin in human gallbladder adenocarcinoma cell lines. Anti-Cancer Drugs. 20(2). 123–130. 8 indexed citations
17.
Shiota, Masaki, Hiroto Izumi, Akihide Tanimoto, et al.. (2009). Programmed Cell Death Protein 4 Down-regulates Y-Box Binding Protein-1 Expression via a Direct Interaction with Twist1 to Suppress Cancer Cell Growth. Cancer Research. 69(7). 3148–3156. 114 indexed citations
18.
Shiota, Masaki, Hiroto Izumi, Takamitsu Onitsuka, et al.. (2008). Twist and p53 reciprocally regulate target genes via direct interaction. Oncogene. 27(42). 5543–5553. 104 indexed citations
19.
Henzan, Hideho, Goichi Yoshimoto, Yoji Nagasaki, et al.. (2004). Myeloid/natural killer cell blast crisis representing an additional translocation, t(3;7)(q26;q21) in Philadelphia-positive chronic myelogenous leukemia. Annals of Hematology. 83(12). 784–788. 6 indexed citations
20.
Cramb, Robert, et al.. (1989). Intraoperative prochlorperazine for prevention of post-operative nausea and vomiting. Canadian Journal of Anesthesia/Journal canadien d anesthésie. 36(5). 565–567. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Islay Steele Breakdown of academic impact, for papers by Feridoon Najmabadi Breakdown of academic impact, for papers by Αναστασία Κοττόρου Breakdown of academic impact, for papers by G Ballabio Breakdown of academic impact, for papers by Huan-Xin Lin Breakdown of academic impact, for papers by Stefan Amatschek Breakdown of academic impact, for papers by Chiyuki Furukawa Breakdown of academic impact, for papers by D Chatterjee Breakdown of academic impact, for papers by Jae Hwi Song Breakdown of academic impact, for papers by Eveline Barbieri
Rankless by CCL
2026